Full-Time

Quality Control Specialist

Posted on 4/29/2025

Deadline 5/14/25
AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Entry, Junior

Liverpool, UK

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • Degree level or equivalent in a scientific discipline
  • Expertise in Quality Control instrumentation
Responsibilities
  • Conduct quality control testing in accordance with cGXP standards
  • Perform routine and non-routine laboratory tasks
  • Lead and support Quality Control investigations
  • Utilize expertise in Quality Control instrumentation to troubleshoot and resolve technical issues
  • Participate in LEAN initiatives to enhance efficiency and sustainability
  • Engage in data analysis, data retention, and reporting
  • Support and respond to regulatory inspections
Desired Qualifications
  • Experience in GMP/GLP environments
  • Understanding of Quality Control testing techniques
  • Previous experience in the biopharmaceutical industry
  • Backgrounds in analytical chemistry or molecular biology

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before reaching the market. AstraZeneca distinguishes itself from competitors by investing heavily in scientific research and forming strategic partnerships to enhance drug discovery. Their goal is to advance healthcare by creating effective treatments for serious diseases and collaborating with other organizations to improve their research capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's new facilities enhance manufacturing capabilities and job creation in key regions.
  • AI-powered tools improve lung cancer detection, showcasing AstraZeneca's innovation in diagnostics.
  • Enhertu's success in breast cancer trials strengthens AstraZeneca's oncology portfolio.

What critics are saying

  • Increased competition in oncology may impact AstraZeneca's market share.
  • Regulatory delays could affect the timely launch of new AstraZeneca products.
  • Emerging biosimilars may erode sales of AstraZeneca's established biologic drugs.

What makes AstraZeneca unique

  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • The company invests heavily in R&D for new drug discovery and development.
  • AstraZeneca's Open Innovation program accelerates drug discovery by sharing resources with scientists.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

The Pharma Letter
May 12th, 2025
AstraZeneca breaks ground on $475 million drug plant in Wuxi

AstraZeneca breaks ground on $475 million drug plant in Wuxi.

MocoShow
May 9th, 2025
AstraZeneca Opens $300 Million CAR-T Manufacturing Facility in Rockville, Creating Over 150 Jobs

AstraZeneca opens $300 million CAR-T manufacturing facility in Rockville, creating over 150 jobs.

Cision
May 9th, 2025
Imfinzi Improved Dfs In Early Bladder Cancer

Imfinzi improved DFS in early bladder cancer

Montgomery County Government
May 9th, 2025
AstraZeneca Opens $300 Million Cell Therapy Manufacturing Facility in Montgomery County

AstraZeneca opens $300 million cell therapy manufacturing Facility in Montgomery County.

PharmiWeb
May 7th, 2025
Enhertu Followed By Thp Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In Patients With High-Risk Her2-Positive Early-Stage Breast Cancer In Destiny-Breast11 Phase Iii Trial

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer. Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. The secondary endpoint of event-free survival (EFS) was not mature at the time of analysis; however, EFS data showed an early positive trend favouring Enhertu followed by THP compared to standard of care. The trial will continue to follow EFS

INACTIVE